Skip to content
Sotorasib, Infigratinib, And More episode artwork

Jun 3, 2021 14 min

Sotorasib, Infigratinib, And More

from OncoPharm Hosted by John Bossaer

Two new drugs approved in the last week: 1. sotorasib, a drug for a specific KRAS mutation (G12C) in 2nd line metastatic NSCLC 2. infigratinib, basically a "me too" FGFR inhibitor approved for metastatic cholangiocarcinoma We all discuss the latest adjuvant CHECKMATE study (nivolumab in urothelial carcinoma) and a recent study of seropositivity in cancer patients following COVID vaccination.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Sotorasib, Infigratinib, And More

0:00 14:18

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of OncoPharm?

This episode is 14 minutes long.

When was this OncoPharm episode published?

This episode was published on June 3, 2021.

Can I download this OncoPharm episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.